BRIEF-Galmed Pharmaceuticals Announces Dosing Of First Subject In First Human Phase 1 Trial Of Amilo-5Mer

Reuters · 03/16/2021 12:57
BRIEF-Galmed Pharmaceuticals Announces Dosing Of First Subject In First Human Phase 1 Trial Of Amilo-5Mer

- Galmed Pharmaceuticals Ltd GLMD.O:

  • GALMED PHARMACEUTICALS ANNOUNCES DOSING OF FIRST SUBJECT IN FIRST IN HUMAN PHASE 1 TRIAL OF AMILO-5MER

Source text for Eikon: ID:nPn6cZwbXa

Further company coverage: GLMD.O


((Reuters.Briefs@thomsonreuters.com;))